Evoke Pharma's - EVOK market analysis on 19th January 2021

Transaction Date	Recipient	Shares	Type	Price	Value
14th December 2020	David A Gonyer	23,954	Open or private sale	$2.94	$70,424.76
11th December 2020	David A Gonyer	48,046	Open or private sale	$2.90	$139,333.40
11th December 2020	Matthew J D'Onofrio	40,357	Open or private sale	$2.91	$117,438.87
10th December 2020	Matthew J D'Onofrio	5,643	Open or private sale	$2.95	$16,646.85
1st September 2020	David A Gonyer	20,238	Other acquisition or disposition	$1.05	$21,249.90
1st September 2020	Matthew J D'Onofrio	20,238	Other acquisition or disposition	$1.05	$21,249.90
1st September 2020	Marilyn R. Carlson	20,238	Other acquisition or disposition	$1.05	$21,249.90
2nd March 2020	Matthew J D'Onofrio	25,000	Grant/award etc.	$0.85	$21,250.00

Evoke Pharma

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.

Evoke Pharma, Inc. develops Gimoti, with promotility and anti-emetic effects. Gimoti is for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus.

Ticker: EVOK

Sector: Health Technology

Industry: Pharmaceuticals: Other

SEC Central Index Key (CIK): 1403708

Employees: 5

Exchange: NASDAQ

Auditor Opinion:

You must Login to see Language Changes

Disclosure Language changes

Analysis of subtle changes in disclosure language. Red is a sign of more constrained, less positive language changes etc. Green is more positive, less constrained etc.

You must Login to see analysis